Indwelling Pleural Catheter for Refractory Hepatic Hydrothorax: The Evidence Is Still Fluid复制标题

留置胸腔导管治疗顽固性肝性胸水: 证据仍是液体

Indwelling pleural catheters (IPCs) have admittedly revolutionized the outpatient management of malignant pleural effusions, providing the same level of symptomatic relief observed with traditional pleurodesis, as supported by a robust body of evidence. 1 Despite the limited data, IPCs received US Food and Drug Administration 510(k) clearance in January 2017 for the management of refractory nonmalignant pleural effusions. They have since been increasingly used in a variety of clinical situations, with several small nonrandomized studies suggesting rates of symptom relief and auto-pleurodesis similar to those seen in malignant pleural effusions (33%-63%). 2,3 One particular area of interest has been the proposed role of IPCs in the management of hepatic hydrothorax, a condition typically characterized by frustratingly limited options.

译文